Skip to main content
Clinical Trials/EUCTR2020-002489-15-SK
EUCTR2020-002489-15-SK
Active, not recruiting
Phase 1

Comparative study of the efficacy and safety of vaginally applied Dequalinium Chloride (10 mg) and orally applied Metronidazole (2 x 500 mg) in the treatment of bacterial vaginosis

Medinova AG0 sites236 target enrollmentDecember 28, 2020

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Medinova AG
Enrollment
236
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 28, 2020
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Premenopausal woman \=18 years
  • 2\. Diagnosis of bacterial vaginosis (all 4 Amsel criteria positive, i.e. 1\) greyish white thin discharge, 2\) KOH test or ‘fishy’ smell, 3\) microscopic presence of \> 20% clue cells, 4\) vaginal pH \> 4\.5\)
  • 3\. Signed Written Informed Consent to participate in this study
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 236
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • 1\. Pregnancy and/or lactation based on urine Pregnancy test (women with childbearing potential should use any contraception excluding vaginal methods like vaginal ring, etc.)
  • 2\. Uterine bleeding (including menstruation) or vaginal bleeding of unknown origin
  • 3\. Ulcerations/erosions of vaginal mucosa or cervix uteri
  • 4\. Patients with clinical symptoms and findings of Candida vulvovaginitis and/or Aerobic vaginitis
  • 5\. Clinically manifest or suspicion of STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, or Trichomonas vaginalis) based on signs, symptoms, and anamnesis
  • 6\. Use of any antimicrobial treatment (local or systemic) 14 days before entry the study
  • 7\. Use of any vaginal medication or vaginal douching 7 days before entry the study
  • 8\. Unwillingness to refrain from alcohol consumption during treatment, and 48 hours after treatment
  • 9\. Severe systemic diseases (HIV, cancer, tuberculosis, autoimmune diseases, diabetes mellitus, severe psychiatric conditions, etc.), including diseases treated with immunosuppressive therapies, systemic corticosteroids, or warfarin
  • 10\. Known or suspected hypersensitivity to one of the study medications, inclusive of their excipients

Outcomes

Primary Outcomes

Not specified

Similar Trials